This process is thought to be at play in ALS (Kanekura et al., 2009). Mutant SOD1 has been found to TSA HDAC molecular weight accumulate in the ER and to inhibit derlin-1, the protein that transports proteins destined to be degraded from the ER to the cytosol (Nishitoh et al., 2008). Furthermore, a decrease in proteasome activity has been found in mutant SOD1-overexpressing cells and tissue (Urushitani et al., 2002; Kabashi et al., 2004, 2008a; Cheroni et al., 2009). Mutant SOD1 thus induces ER stress, and may overload the UPR response and the proteasome system. Upregulation of ER stress molecules has been correlated with the vulnerability of motor neurons in mutant SOD1 mice

(Saxena et al., 2009). Overexpression of heat-shock proteins (HSPs) in vitro rescues the cell from mutant SOD1-induced

toxicity (Patel et al., 2005). Disappointingly, neither HSP27 nor HSP70 overexpression in vivo affected motor neuron degeneration in mutant SOD1 mice (Liu et al., 2005; Krishnan et al., 2008). It is obvious that overexpressing one component of this sophisticated system may be insufficient. The misfolded mutant SOD1 that escapes the cellular degradation system may interact with aberrant binding partners (such as mitochondrial membranes or chromogranins; see above) or form oligomers which then may proceed to the formation of higher molecular species and finally aggregate into intracellular Epigenetic inhibitor inclusions (Johnston et al., 2000; Rakhit et al., 2002; Ezzi et al., 2007; Teilum et al., 2009). It is thought but not certain that this process is toxic for the neuron. Which stage of formation of inclusions is responsible for toxicity is uncertain, as is the question whether wildtype SOD1, which can form heterodimers with mutant SOD1 or can be recruited to coaggregate with it, contributes to this toxicity (Bruijn et al., 1998; Jaarsma et al., 2000; Fukada et al., 2001; Lemmens et al., 2007;

Wang et al., 2009b). Aggregates may deplete the cell of essential constituents by coaggregation, or may physically disturb cellular processes such axonal transport (axonal strangulation; De Vos et al., 2007). However, just like for many other neurodegenerative diseases, it remains Teicoplanin unknown whether aggregation of mutant protein is a hazardous or a protective phenomenon. It may well be that the first stages of the process (oligomerisation) are toxic (Johnston et al., 2000; Wang et al., 2002) while the aggregates themselves are essentially inert. The convergence of damage in non-neuronal cells surrounding motor neurons has a larger impact on motor neuron survival then initially anticipated (Ilieva et al., 2009). Several types of non-neuronal cells, such as microglia and astrocytes, are activated in the course of the neurodegenerative process in ALS (Hall et al., 1998).

It is possible that this is caused by the binding of ACEA to CB2 receptors at micromolar concentrations (Ki of 3 ± 1 μm; Hillard et al., 1999). There is evidence for the expression of CB2 receptors in neurons and glia throughout selleck the CNS (Gong et al., 2006), including

in the spinal cord and primary afferents (Beltramo et al., 2006). ACEA is also a TRPV1 agonist at micromolar concentrations (Price et al., 2004). However, opening of TRPV1 channels by ACEA would further increase substance P release (Marvizon et al., 2003a), so this could not explain the reversal of the increase in NK1R internalization at high concentrations of ACEA. Our results are at variance with those of Lever & Malcangio (2002), who found that capsaicin-induced substance P release from mouse spinal cord slices was considerably increased by the CB1 antagonist rimonabant and inhibited by the endocannabinoid anandamide. Epigenetic inhibitor nmr However, they used rimonabant at a dose, 5 μm, at which it may activate other receptors such as adenosine A1 receptors (Savinainen et al., 2003). We found that the inhibition of NK1R internalization produced by rimonabant and AM281 disappeared at micromolar doses.

As for anandamide, its inhibition could have been mediated by receptors other than CB1 that also bind anandamide, such as CB2 receptors (Devane et al., 1992; Kano et al., 2009) and TRPV1 (Zygmunt et al., 1999; Starowicz et al., 2007). AM251 is also an agonist of the novel cannabinoid receptor GPR55 (Ryberg et al., 2007;

Kano et al., 2009). However, its inhibition of substance P this website release cannot be attributed to this receptor for various reasons. First, unlike AM251, the GPR55 agonist O-1640 (Johns et al., 2007; Oka et al., 2007; Waldeck-Weiermair et al., 2008) did not inhibit NK1R internalization evoked by dorsal root stimulation (Fig. 2B). Second, like AM251, rimonabant (which acts as an antagonist of GPR55; Ross, 2009) inhibited NK1R internalization. Third, AM281, which is ineffective at GPR55 (Ross, 2009), also inhibited NK1R internalization. TRPV1 channels are activated by some endocannabinoids (Kano et al., 2009). However, the effects of the synthetic cannabinoids used in this study cannot be attributed to TRVP1 either, because NK1R internalization induced by direct application of capsaicin to the slices was not inhibited by AM251 (Fig. 6B). We have previously shown (Lao et al., 2003) that capsaicin-induced substance P release bypasses the inhibition produced by GABAB receptors and probably other GPCRs. This is because GPCRs inhibit substance P release by inactivating voltage-dependent Ca2+ channels (Strock & Diverse-Pierluissi, 2004; Raingo et al., 2007), whereas TRPV1 channels provide an alternative route for Ca2+ entry into the terminal that bypasses the voltage-dependent Ca2+ channels. The inhibition of substance P release by the CB1 antagonists AM251, AM281and rimonabant is probably caused by blockade of the effect of endocannabinoids released in the dorsal horn.

Hypertension was the most frequent type of CVD. However, the recorded frequency of CVD in high-altitude mountaineers is lower compared to hikers and alpine skiers. Mountain Selleckchem SP600125 sports have become very popular, and the number of tourists visiting altitudes above 2,000 m worldwide is estimated to be more than 100 million per year.1 The majority of them perform alpine skiing or hiking. High-altitude mountaineering represents a further popular mountain sport in high mountain areas. High-altitude mountaineering in this article is defined as (1) ascending

on foot to altitudes >3,000 m and (2) crossing glaciers using harness, rope, and, if necessary, crampons. High-altitude mountaineers hike on trackless terrain (eg, snow, rocky passages, and glaciers) with rather heavy equipment. The characteristics of high-altitude mountaineering challenge the technical skills and endurance of the participants and can elicit high exercise intensities. Therefore,

high-altitude mountaineering has to be distinguished from other mountain sports such as alpine skiing, hiking, or ski mountaineering. High-altitude mountaineering is associated with manifold risks (eg, slips and falls, breaking into crevasses), but about 50% of all Selleckchem BMN 673 fatalities during mountain sport activities are sudden cardiac deaths.2 Although sojourns at moderate altitude are well tolerated by persons with cardiovascular diseases (CVD),3 preexisting CVD are associated with an increased risk for fatal and nonfatal cardiac events during high-intensity exercise and mountain sports.2,4,5 Previous studies on different mountain sport activities have shown a mountain sport-specific prevalence of CVD. The frequency of persons with known CVD was 12.7% in hikers and 11.2% in alpine skiers,6 whereas it was considerably lower (5.8%) in disciplines with high psychophysiological demands such as ski mountaineering.7

This might also be assumed for high-altitude mountaineers. Despite the increasing popularity and the specific conditions of high-altitude mountaineering, epidemiological CYTH4 data on its participants are lacking. Therefore, the goal of this survey was to evaluate the prevalence of preexisting CVD among high-altitude mountaineers. We studied a cohort of high-altitude mountaineers (target sample size n = 500) using a standardized questionnaire (in German), which was tested previously and revised to improve clarity and time efficiency. The questionnaire was validated in patients with various diseases and healthy persons (n = 20). For this purpose, the medical diagnoses of the persons were compared with the results of the questionnaires. The calculated sensitivity and specificity amounted to 100 and 93%, respectively.

The primers used for the Q-PCR were as follows: for SpHtp1 5′-CGTCATCATCGGAGAAATCC-3′ (forward) and 5′-CGCTTTGTTCAAGTTGTTCC-3′ (reverse); for SpTub-b 5′-AGGAGATGTTCAAGCGCGTC-3′ (forward) and 5′-GATCGTTCATGTTGGACTCGGC-3′ (reverse). For analysis, a standard curve of a pool of the cDNA of all samples was included to normalize the transcript levels. Subsequent analysis was performed with lightcycler® 480 software release 1.5.0 (Roche), using the second derivative maximum method, which calculates and includes PCR efficiency according to Pfaffl (2001). Q-PCR analysis was performed GSK2118436 cell line with three technical replicates of four independent RNA isolations (biological

replicates). Statistically significant differences were determined by anova (P<0.05), followed by the Bonferroni post hoc multiple comparison. A 1406-bp fragment containing SpHtp1 and Selleckchem ABT-888 including flanking regions was amplified from genomic DNA by the primers 5′-GTTTGAATGGAGCAGCGTGCT-3′ (forward) and 5′-TACGATGAATTCTAATCGAATGTCGGGACGACCTGG-3′

(reverse) and subsequently sequenced. The obtained sequence was analysed for the start and the stop codon and the oomycete promoter region. For overexpression, a fragment of SpHtp1 was amplified, encoding for amino acids (aa) 24-198 lacking the putative N-terminal signal peptide and the C-terminal stop codon. The fragment was amplified by PCR from mycelial cDNA using KOD-Hot start DNA polymerase (Novagen) at an annealing temperature of 55 °C and in the presence of 3% DMSO. The primers used were 5′-GGGCGCATATGCGCATTCACCACCCGTTGACC-3′ (SpHtp124-198 forward) and 5′-CCGGGAATTCGGATCGAATGTCGGGACG-3′ (SpHtp124-198 reverse). The forward primer contained an NdeI and the reverse primer contained an EcoRI restriction site. The blunt end PCR-product was cloned into pETblue-2 (Novagen) and, after

NdeI and EcoRI digestion and gel purification, cloned into the NdeI- and EcoRI-digested PLEKHB2 vector pET21b (Novagen) in frame with the (His)6 tag. The resulting plasmid SpHtp124-198-(His)6 was checked by sequencing and transformed into Rosetta gami B Escherichia coli cells (DE3, pLys; Novagen). SpHtp124-198-(His)6-overexpressing cells were grown in Luria–Bertani media to an OD600 nm of 0.6–0.8 and induced with 1 mM IPTG for 6 h at 37 °C. Cells were centrifuged and the pellet was resuspended in 40 mL of 50 mM sodium phosphate (pH 7.1) and incubated with 250 U of benzonase (Sigma-Aldrich), two dissolved tablets of protease inhibitor (Roche) and 0.1 g lysozyme (Fluka). After a 30-min incubation on ice, the solution was French-pressed and diluted 1 : 5 in 25 mM sodium phosphate buffer (pH 7.0) before the soluble fraction was separated from the nonsoluble via centrifugation at 48 000 g for 1 h. The supernatant was applied to a Fractogel-EMD-SO3-column (Merck, 2 cm diameter × 15 cm) and washed with 10 volumes of 25 mM sodium phosphate buffer (pH 7.0) containing 25 mM potassium chloride.

This case report describes a substantial reduction in serum insulin concentrations using surgical excision of the single injection site after a severe overdose of insulin glargine and insulin aspart. Copyright © 2012 John Wiley & Sons. “
“Views of young people with type 1 diabetes are vital in developing quality services and improving health-related quality of life (HRQoL), yet research on their lifestyle and use of web and mobile technology

to support their condition and in non-health related areas is sparse. The aim of this research was to develop an insight into young BTK activity people’s current use of web and mobile technology and its potential impact on HRQoL by constructing an in-depth picture of their day-to-day experiences, exploring how they made use of technology in their lives and in relation to their condition and treatment – then, building something to help them. Data were collected by semi-structured, in-depth qualitative interviews (n=9) of young people with type 1 diabetes and aged 18–21 years. Interviews were transcribed and loaded onto NVivo for theme identification. Data analysis was also undertaken during initial interviews (n=4) to locate potential ideas for technical development. Latter interviews (n=5) assisted in the iterative sociotechnical Selleck Dabrafenib design process. Three suggestions for improvement were taken forward

for prototyping with one – an alcohol education guide – being developed into a clinically approved app. This article documents the procedures and sociotechnical design principles involved in the creation of a patient-centric app. It provides an innovative example of how education with the aim of improving Adenosine HRQoL can be designed in a way which meets the needs of a particular group and values and encourages their input to assist in the creative process, while at the same time conforming to clinical guidelines. Copyright © 2013 John Wiley & Sons. “
“An accurate and valid district diabetes register is needed to identify people with diabetes. Quality assurance of such a register is vital to deliver high-standard patient care. We report the findings of a methodical process of validation of the Wolverhampton District Diabetes Register

(WDDR) post extraction of information from general practitioner (GP) databases, and propose an algorithm for resolving any disparity between the two data registers. Historic diabetes register data were matched with GP databases; discrepancies were checked with GP practices and updated on the WDDR. Unidentifiable people were subject to demographic checks with the Demographic Batch Service (DBS). DBS information was used to identify patients by contacting them directly or by contacting their GP practices. Diagnostic discrepancies were corrected by biochemical checks or identifying coding errors in the GP database. Of 2565 people unmatched with GP databases, 2380 had an identifiable GP. After checking with GP practices, 1244 (48.5%) were identified to have coding errors, 61 (2.

, 2005; Pisareva et al., 2007), most likely due to the poor solubility and low abundance of membrane proteins in general. One of the TatA/B homologues (slr1046) could be visualized in the thylakoid membranes when fused to GFP (Aldridge et al., 2008). It remained unclear whether it was also present in the plasma membrane, and currently no data are available on the localization of ssl2823. An analysis of the 25 different cyanobacterial genomes reveals the presence of putative Tat pathway components in all cases (Table 1). Each of them possesses a single

TatC Epacadostat homologue, with the only exception being Synechococcus JA-3-3Ab that interestingly has an additional truncated TatC (cya_1280). This truncated version of TatC comprises only two predicted transmembrane domains compared to the usual six found in TatC proteins and its function in the Tat pathway remains to be experimentally verified. Amongst many of the marine cyanobacteria strains, the tatC gene is localized in a relatively well-conserved cluster that includes the predicted petC Tat substrate (Fig. 1) that is a component of the Cytochrome b6-f complex. Also, noteworthy is the close localization of the csaA gene with tatC in the two Nostoc species studied, and an example of one of these (Nostoc punctiforme Vorinostat supplier ATCC29133) is shown in Fig. 1. CsaA is a translocation associated chaperone

thought to be functionally similar to E. coli SecB that is involved in the translocation of some Sec-pathway substrates; so far, it has not been shown to participate in Tat-dependent translocation. Also intriguing is the localization of a natural resistance macrophage protein (Nramp) encoding gene between the tatC and petC genes of Nostoc punctiforme ATCC29133 (Fig. 1). Nramp proteins are metal ion transporters that

have been found to transport Mn2+ and Fe2+ (Makui et al., 2000), and this close localization with PetC and TatC may suggest a role in the delivery of iron to PetC. A blast search against the sequences of the Tat proteins of Synechococcus sp. WH8102 also reveals that many of the 25 genomes analysed have just a single TatA/B Thymidine kinase homologue, strongly indicating the widespread use of minimal TatAC systems in these species, although we cannot rule out the existence of other more divergent TatA like proteins. However, some of the strains analysed do have two separate TatA/B homologues and again it remains unclear whether these cyanobacteria have TatABC or TatAC-type translocases. The presence of two separate TatA/B proteins in many of the Prochlorococcus strains is surprising as these have the smallest cyanobacterial genomes and the fewest predicted Tat substrates of the strains studied (Tables 1 and S1). One of the two tatA genes of Synechococcus JA-3-3Ab (cya_0761) is localized with genes encoding FtsY and SecA that are required for protein translocation via the signal recognition particle pathway and general secretory pathway (Du Plessis et al., 2011) respectively (Fig. 1).

The structural component of the basement layer of the coat is an exceptional cytoskeletal protein, termed SpoIVA, which binds and hydrolyzes ATP. ATP hydrolysis is utilized to drive a conformational change in SpoIVA that leads to its irreversible

self-assembly into a static selleck inhibitor polymer in vitro. Here, we characterize the middle domain of SpoIVA, the predicted secondary structure of which resembles the chemotaxis protein CheX but, unlike CheX, does not harbor residues required for phosphatase activity. Disruptions in this domain did not abolish ATP hydrolysis, but resulted in mislocalization of the protein and reduction in sporulation efficiency in vivo. In vitro, disruptions in this domain prevented the ATP hydrolysis-driven conformational change in SpoIVA required for polymerization and led to the aggregation of SpoIVA into particles that did not form filaments. We propose a model in which SpoIVA initially assumes a conformation in which it inhibits its own aggregation into particles, and that ATP hydrolysis remodels the protein so that it assumes www.selleckchem.com/products/bmn-673.html a polymerization-competent conformation. “
“Edwardsiella tarda is a Gram-negative, facultative aerobic pathogen which infects multifarious hosts

including fish, amphibians and human beings. A twin-arginine translocation (Tat) gene cluster important for high-salt tolerance in E. tarda was identified previously. Here the genetic structure and pleiotropic roles of the Tat system in physiological adaptation of the bacterium were

further characterized. Functional analysis indicated that tatD was not required for Tat export process and tatE might be an allelic gene of tatA in the bacterium. The results showed that disruption in the Tat system did not affect the morphology and biofilm formation in E. tarda, but did affect motility, hemagglutination, cell aggregation and Amine dehydrogenase infection of eukaryotic cells (e.g. macrophage J774a). Comparative proteomics analysis of subcellular proteins using two-dimensional gel electrophoresis and a qualitative shotgun protein sequencing method were implemented to identify proteins differentially expressed in E. tarda EIB202 vs. ∆tatABCD. The results revealed a large repertoire of differentially expressed proteins (n = 61), shedding light on the Tat system associated with virulence and stress-associated processes in E. tarda. “
“In this study, we show the expression of flavin mononucleotide-based fluorescent protein (FbFP) BS2 as a marker for gene expression in the opportunistic human anaerobic pathogen Bacteroides fragilis. Bacteroides fragilis 638R strain carrying osu∷bs2 constructs showed inducible fluorescence following addition of maltose anaerobically compared with nonfluorescent cells under glucose-repressed conditions. Bacteria carrying ahpC∷bs2 or dps∷bs2 constructs were fluorescent following induction by oxygen compared with nonfluorescent cells from the anaerobic control cultures.

The effects of various opposing torques produced by the antagonist were also measured. As a result, the suppressing effect of cTBS was enhanced by mild antagonist contraction, whereas effortful antagonist contraction suspended the plasticity caused by cTBS. In contrast, the antagonist contractions right after cTBS did not significantly influence the effect of cTBS. The results indicate that the antagonist activity alters the effect of cTBS, especially in protocols Selleck INCB024360 with synchronous magnetic stimulation and antagonist contraction. Such modulation on cTBS may be through a reciprocal

mechanism within the motor cortex, although the spinal regulation of the motoneuronal pool cannot be fully excluded. The present findings are beneficial for elucidating the mechanism of neuromuscular control and for resolving related neurological disorders. “
“Auditory

evoked potentials (AEPs) to motion onset in humans are dominated by a fronto-central complex, with a change-negative deflection 1 (cN1) and a change-positive deflection 2 (cP2) component. Here the contribution of veridical motion detectors to motion-onset AEPs was investigated with the hypothesis that direction-specific adaptation effects would indicate the contribution of such motion detectors. AEPs were recorded from 33 electroencephalographic channels to the test stimulus, i.e. motion onset of horizontal virtual auditory motion (60° per s) from straight ahead to the left. AEPs were compared in two experiments for three conditions, which differed in their history

prior to the motion-onset Talazoparib in vitro test stimulus: (i) without motion history (Baseline), (ii) with motion history in the same direction as the test stimulus (Adaptation Same), and (iii) a reference Amine dehydrogenase condition with auditory history. For Experiment 1, condition (iii) comprised motion in the opposite direction (Adaptation Opposite). For Experiment 2, a noise in the absence of coherent motion (Matched Noise) was used as the reference condition. In Experiment 1, the amplitude difference cP2 − cN1 obtained for Adaptation Same was significantly smaller than for Baseline and Adaptation Opposite. In Experiment 2, it was significantly smaller than for Matched Noise. Adaptation effects were absent for cN1 and cP2 latencies. These findings demonstrate direction-specific adaptation of the motion-onset AEP. This suggests that veridical auditory motion detectors contribute to the motion-onset AEP. “
“The N1m is an evoked magnetic field in auditory cortex that is automatically elicited by tones in silence but not in the context of multiple other tones: when listeners are unaware of a tone stream because of informational masking, no N1m-like activity is observed. In contrast, N1m-like activity is evoked when listeners are aware of the regular tone stream in the same context but in another trial. Here we compared this awareness-related negativity (ARN) with the automatic N1m.

At the completion of the lesion, the wound was closed in anatomical layers. Nonsteroidal anti-inflammatory analgesic (0.2 mg/kg meloxicam, orally) and antibiotic (8.75 mg/kg amoxicillin, orally) treatment was administered for 5 days postoperatively. All surgery was carried out under sterile conditions with the aid of a binocular microscope. The wound was closed in anatomical layers. At least 2 weeks were allowed for recovery before testing resumed. When the animals had completed their testing they were anesthetized with sodium pentobarbitone and perfused with 90% saline and 10% formalin. The brains

were then removed and placed in 10% sucrose formalin until they sank. The brains were blocked in the coronal plane at the level of the most medial part of the central sulcus. Each brain was cut in 50-μm coronal CP-868596 datasheet sections. Every tenth section was retained for analysis and stained with Cresyl violet. All training and testing was conducted while the animals were in a transport cage inside a

modified Wisconsin General Testing Apparatus (WGTA; Fig. 1A). HDAC inhibitor A Plexiglas box measuring 70 × 11 × 11 cm with a hinged back was fixed to the WGTA 20 cm in front of the transport cage. In addition behind the box, 50 cm from the front of the transport cage, was a PC monitor for presenting visual stimuli. On each trial, stimuli could be presented either in the box or on the PC monitor. The stimuli presented in the box could be one of the following: 20 neutral control ‘junk’ objects and two fear-inducing stimuli (a static rubber snake or a moving wooden snake).

Stimuli presented on the screen were video clips 30 s in length and were one of two human stimuli (two unknown staring human faces), one of five social stimuli [a large (11 kg) monkey staring, a monkey (8 kg) exhibiting affiliative behaviours (lip-smacking), a monkey (9 kg) inspecting a transport cage or a monkey (5 kg) with food, and a female macaque (5 g) with prominent perineal swelling] or a moving, neutral control stimulus (a moving randomly changing coloured object; Fig. 3B). The video clips were chosen because it made it possible to compare the effects of mOFC lesions with the effects of ACCg lesions; the stimuli had previously been used in an investigation of the effects of ACCg lesions (Rudebeck Methocarbamol et al., 2006). The social stimuli were chosen because they were expected to elicit varying degrees of interest from control monkeys (and indeed this proved to be the case as explained below). Video stimuli were clips taken from longer videos of other monkeys in the colony recorded while they were in either transport cages or primate chairs. At the time of testing all the monkeys in the video social stimuli were novel to the subjects. All videos were taken using a Panasonic EZ35 mini-DV camera and edited using Adobe Premier Pro 1.5 software. Videos were played using Windows media player version 9.0.

G-CSF 930101 Study Group. AIDS 1998; 12: 65–74. 41 Kuritzkes DR. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating

factor. Clin Infect Dis 2000; 30: 256–260. 42 Tomblyn M, Chiller T, Einsele H et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143–1238. 43 Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect www.selleckchem.com/products/pexidartinib-plx3397.html Dis 2011; 52: e56–93. 44 Cullen M, Steven N, Billingham L et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353: 988–998. 45 Engels EA, Lau Ku-0059436 J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16: 1179–1187. 46 Baden LR. Prophylactic antimicrobial

agents and the importance of fitness. N Engl J Med 2005; 353: 1052–1054. 47 Flowers CR, Seidenfeld J, Bow EJ et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31: 794–810. 48 Saral R, Burns WH, Laskin OL et al. Acyclovir

prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981; 305: 63–67. 49 Saral R, Ambinder RF, Burns WH et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled oxyclozanide study. Ann Intern Med 1983; 99: 773–776. 50 Boeckh M, Kim HW, Flowers ME et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation–a randomized double-blind placebo-controlled study. Blood 2006; 107: 1800–1805. 51 Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49(RR-10): 1–125 CE121–127. 52 Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815–2820. 53 Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063–4071. 54 Beck CR, McKenzie BC, Hashim AB et al.